🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

NEPHROCARE HEALTH SERV L NEPHROPLUS NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.nephroplus.com
Company Profile ↓
₹655.00
+38.99% 1Y
Mkt Cap₹6,572.32 Cr
P/E80.86
P/B5.76
52W High₹751.30
52W Low₹449.15
Book Value₹111.27
EPS (TTM)₹8.10

Company Overview

Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 250.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 34.1% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹998.85 Cr (+32.2% YoY); net profit ₹76.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +32.2%, earnings +14.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 34.1%, profit CAGR 250.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:34.07%
1 Year:32.16%

Compounded Profit Growth

5 Years:250.60%
1 Year:14.52%

Stock Price Performance

1 Year:+38.99%
6 Months:+33.58%
3 Months:+17.00%
1 Month:-8.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 68% of range
₹449.15 ₹751.30
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)47.27 · Neutral
Price Performance
1M-8.19%
3M+17.00%
6M+33.58%
1Y+38.99%
Valuation vs Sector

P/E of 80.86 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 34.1% over 5 years.
  • Profit CAGR of 250.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 80.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
80.86
Industry PE
39.97
Forward P/E
32.12
PEG Ratio
-
Book Value
₹111.27
Price to Book
5.76
P/S
6.44
EV/EBITDA
26.81
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
34.07%
Profit 5Y
250.60%
Revenue (YoY)
32.16%
Earnings (YoY)
14.52%

Profitability & Returns

ROCE
13.46%
ROE
6.88%
ROA
5.22%
Profit Margin
7.69%
Op Margin
13.65%
Gross Margin
40.86%
EPS (Latest Qtr)
₹2.96
EPS (TTM)
₹8.10

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
2.69
Current Ratio
2.80
Debt
₹79.71 Cr
Total Assets
₹1,470.87 Cr
Current Assets
₹839.17 Cr
Working Capital
₹539.76 Cr

Ownership

Promoter Holding
54.73%
Chg in Prom Hold
-9.12%
FII / Inst Holding
30.75%
Chg in FII Hold
-1.12%

Financial Snapshot

Enterprise Value
₹6,572.32 Cr
Total Revenue (TTM)
₹998.85 Cr
EBITDA
₹248.38 Cr
Free Cash Flow
₹113.22 Cr
Operating Cash Flow
₹232.58 Cr
Shares Outstanding
₹10.03 Cr
Gross Margin
40.86%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NEPHROPLUS NEPHROCARE HEALTH SERV L NSEPHARMA 655.00 80.86 ₹6,572.32 Cr 0.00% 13.46% 6.88% 34.07% 250.60%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue 197.26 Cr219.19 Cr246.00 Cr259.73 Cr265.62 Cr
Cost of Revenue 120.32 Cr130.11 Cr-152.29 Cr156.09 Cr
Gross Profit 76.94 Cr89.08 Cr-107.43 Cr109.53 Cr
Operating Expenses 51.01 Cr57.16 Cr182.00 Cr68.43 Cr81.61 Cr
Operating Income 25.92 Cr31.93 Cr41.00 Cr39.00 Cr27.92 Cr
EBITDA 49.46 Cr55.41 Cr64.00 Cr64.18 Cr62.24 Cr
Interest Expense 4.85 Cr6.12 Cr45.00 Cr5.96 Cr3.18 Cr
Pretax Income 26.43 Cr29.92 Cr-1.00 Cr36.36 Cr33.22 Cr
Tax Provision 6.33 Cr5.05 Cr-14.27 Cr4.12 Cr2.85 Cr
Net Income 20.11 Cr24.87 Cr-9.00 Cr32.24 Cr30.37 Cr
Diluted EPS 2.002.48-5.243.352.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 286.00 Cr-414.52 Cr539.55 Cr755.81 Cr998.85 Cr
Cost of Revenue --311.03 Cr368.69 Cr474.90 Cr590.72 Cr
Gross Profit --103.50 Cr170.86 Cr280.91 Cr408.12 Cr
Operating Expenses 248.00 Cr-99.85 Cr117.38 Cr186.74 Cr271.83 Cr
Operating Income 3.00 Cr-3.64 Cr53.47 Cr94.17 Cr136.30 Cr
EBITDA 37.00 Cr-52.87 Cr107.05 Cr180.74 Cr248.38 Cr
Interest Expense 7.00 Cr-14.59 Cr19.00 Cr20.83 Cr60.24 Cr
Pretax Income 1.00 Cr--8.59 Cr33.16 Cr87.44 Cr97.47 Cr
Tax Provision 31.00 L-3.20 Cr-1.97 Cr20.34 Cr20.63 Cr
Net Income 1.00 Cr--11.79 Cr35.13 Cr67.10 Cr76.84 Cr
Diluted EPS 3.40--1.173.506.698.10

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 428.00 Cr-666.23 Cr806.02 Cr996.46 Cr1,470.87 Cr
Current Assets --324.25 Cr390.03 Cr545.36 Cr839.17 Cr
Cash & Equivalents --13.19 Cr61.15 Cr125.82 Cr123.89 Cr
Inventory --26.27 Cr25.91 Cr26.62 Cr33.04 Cr
Receivables --158.50 Cr202.67 Cr266.42 Cr316.89 Cr
Total Liabilities --277.60 Cr392.31 Cr412.35 Cr354.37 Cr
Current Liabilities --174.61 Cr242.59 Cr283.89 Cr299.41 Cr
Long Term Debt --81.48 Cr123.24 Cr96.00 Cr4.70 L
Total Debt 140.00 Cr-213.73 Cr267.84 Cr257.78 Cr79.71 Cr
Total Equity 247.00 Cr-388.63 Cr413.71 Cr584.11 Cr1,116.49 Cr
Shares Outstanding --10.03 Cr10.03 Cr10.03 Cr10.03 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 32.00 Cr-11.27 Cr72.28 Cr135.35 Cr232.58 Cr
Investing Cash Flow -62.00 Cr--78.21 Cr-50.66 Cr-125.07 Cr-410.44 Cr
Financing Cash Flow 36.00 Cr-59.97 Cr26.74 Cr54.37 Cr157.11 Cr
Capital Expenditure -61.00 Cr--73.74 Cr-80.00 Cr-100.80 Cr-119.36 Cr
Free Cash Flow -29.00 Cr--62.47 Cr-7.72 Cr34.55 Cr113.22 Cr
Net Change in Cash 5.00 Cr--6.97 Cr48.36 Cr64.64 Cr-20.75 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --25.0%31.7%37.2%40.9%
Operating Margin % 1.0%-0.9%9.9%12.5%13.6%
Net Margin % 0.3%--2.8%6.5%8.9%7.7%
ROE % 0.4%--3.0%8.5%11.5%6.9%
ROCE % --0.7%9.5%13.2%11.6%

Shareholding Pattern

Insiders
54.73%
Institutions
30.75%
Public Float
67.91%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEPHROPLUS

Google News Sun, 17 May 2026

NEPHROPLUS Stock Price and Chart — NSE:NEPHROPLUS - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBBa3cxeXJOY1QtbVIxUWpRYjA5R1dzYVVPeDdVWXQycEQ5N1ZGOVNaajBxbjZKUUVXaU83M21WZ1hyQktiLTh6ajltT0tXOHNZbWxldzVNMWRKZ0lzYVBlcA?oc=5" target="_blank">NEPHROPLUS Stock Price and Chart — NS…

Google News Wed, 17 Dec 2025

Nephrocare Health Services Ltd Share Price Today – Live NSE/BSE - INDmoney

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE96clZqeHF1aHZIOXM4RWhBR1p0Qlkxb29mMTlzb2I2VUdYMDRJUmlkZldBa01FWWZ0LXR6akNQZV9SbldZLVIycEZyR1Q2RVhybEdsTHh0ZGlrenEySkVfWHJSbmM1ck5ydjY1SkxuVjNiZ3dlOU1kUnRqNDlSdnM?oc=5" target="_bla…

Google News Wed, 10 Jun 2026

NEPHROPLUS to acquire dialysis center assets in Paranaque City, Philippines - Business Standard

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPR3l5NlJyc2otRzNoM08xWnV0WHZuUTdBdUUyZzZyWlBuWmRIU3BsX0J0aXEzU0FldFVGNmFKYWdEQ2NQXzdTUFY2eDJjUGlkQmkxblpBMVYtb2ZjX3hEUWVCTGFYbjBxSlExUnByb3JlWUU1bXNaQkViams1QlVUdmxPdnJOcTRzMHB1ck…

Google News Mon, 22 Jun 2026

Nephrocare Health Services approves ESOP 2026 and INR 70 Cr Saudi collateral - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYm44LWQwclNIMmMyaTJXODkwWmFFQmJWWS14Zm83SlNfNHJ0NnlFZjVsd3FvUEFKUkFSaDhELXRtX1lHWUEzbXB2NkV6ME9ZQUZXeXBIdmlENzM2aWhLOF9Va2EwemhiVVZRYkxWZlMxczNQSThCSVpJQWtaSjVwZDk0N20xN3JSXzgzZz…

Google News hu, 08 Jan 2026

Nephrocare Health Services Ltd | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTFBDYzNBRmVVTV9wQWlvaFFXNldZd3RfWDd2SXRCNUpzeHdFNDRLNTU0djBtMHd3T2lQcUs4eVkxTXE1M2dWLVBZTnlVcVVuRDRrblRfUzdCTnJzcWNGMmZ2VGV0cDFwSGo5Nmt5STVWdU41NnNLYmw1ZnFocw?oc=5" target="_blank">N…

Google News Wed, 20 May 2026

NephroPlus expects 15-20% revenue growth as India, overseas expansion picks up - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMigwJBVV95cUxQdU9RT2twVkNxUDdvWTZ2U2lMSkQzMGk0ZV8tbXlHcDZ3ZF92c1gxMTdnZnl4T2FVVXFPdlRtRmVqNzdXZnIzUnl6a0tNRXBQSy02YXRaLUk5OExENXJ2VTNaSWNsTlg3UWJCam9VMTRhMUh6RDB4VzdKY0xVdkZIQmh3ZDhSYk1jSkVkcF…

NEPHROPLUS — Frequently Asked Questions

What is the current share price of NEPHROCARE HEALTH SERV L (NEPHROPLUS)?

As of 2026-07-15 09:52 IST, NEPHROCARE HEALTH SERV L (NEPHROPLUS) trades at ₹655.00 on NSE. Its 52-week range is ₹449.15 to ₹751.30.

What is the market capitalisation of NEPHROPLUS?

NEPHROCARE HEALTH SERV L (NEPHROPLUS) has a market capitalisation of ₹6,572.32 Cr on NSE.

What is the P/E ratio of NEPHROPLUS?

NEPHROPLUS trades at a trailing price-to-earnings (P/E) ratio of 80.86. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.76.

What is the return on equity (ROE) of NEPHROPLUS?

NEPHROPLUS has a return on equity (ROE) of 6.88%. Its return on capital employed (ROCE) is 13.46%.

Is NEPHROPLUS a good stock to buy?

This page provides a data-driven analysis of NEPHROCARE HEALTH SERV L (NEPHROPLUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space